FGF23 and the parathyroid glands
- 5 June 2010
- journal article
- review article
- Published by Springer Nature in Pediatric Nephrology
- Vol. 25 (11) , 2241-2245
Abstract
Fibroblast growth factor 23 (FGF23) is a phosphatonin that is secreted by osteocytes and osteoblasts in response to hyperphosphatemia and 1,25-dihydroxyvitamin D (1,25D). It acts on its receptor complex, Klotho–FGFR1c (fibroblast growth factor receptor 1 c-splicing form), in the distal convoluted tubule to repress renal phosphorus reabsorption in the proximal tubule and suppress the renal synthesis of 1,25D. Klotho–FGFR1c is also expressed in the parathyroid glands. FGF23 acts on the receptor complex in the parathyroid glands to decrease parathyroid hormone (PTH) gene expression and PTH secretion through activation of the MAPK pathway. In chronic kidney disease (CKD), both FGF23 and PTH are increased, implying resistance of the parathyroid glands to FGF23. There is a decrease in the Klotho–FGFR1c complex in the parathyroid glands in both experimental CKD and in patients with end-stage renal disease. In addition, in advanced experimental CKD, FGF23 has a decreased ability to inhibit PTH expression.Keywords
This publication has 35 references indexed in Scilit:
- Circulating Fibroblast Growth Factor 23 in Patients with End-Stage Renal Disease Treated by Peritoneal Dialysis Is Intact and Biologically ActiveThe Journal of Clinical Endocrinology & Metabolism, 2010
- Fibroblast growth factor-23 and early decrements in kidney function: the Heart and Soul StudyNephrology Dialysis Transplantation, 2009
- Patterns of FGF-23, DMP1, and MEPE expression in patients with chronic kidney diseaseBone, 2009
- Relationship between circulating FGF23 and total body atherosclerosis in the communityNephrology Dialysis Transplantation, 2009
- High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patientsNephrology Dialysis Transplantation, 2009
- Endocrine functions of bone in mineral metabolism regulationJournal of Clinical Investigation, 2008
- Fibroblast Growth Factor 23 and Mortality among Patients Undergoing HemodialysisNew England Journal of Medicine, 2008
- Postprandial Mineral Metabolism and Secondary Hyperparathyroidism in Early CKDJournal of the American Society of Nephrology, 2008
- The parathyroid is a target organ for FGF23 in ratsJournal of Clinical Investigation, 2007
- Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolismNature Genetics, 2006